BCYC
Bicycle Therapeutics plc
BCYC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BCYC overall, supported by stronger fundamentals and stronger modeled upside.
BCYC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BCYC's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BCYC PE Valuation
BCYC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BCYC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BCYC's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BCYC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | +$1.61 |
| Q2 2026 | -$2.73 | +$0.80 |
| Q1 2026 | -$3.15 | +$0.01 |
| Q4 2025 | -$3.16 | -$0.26 |
| Q3 2025 | -$3.64 | -$0.40 |
| Q2 2025 | -$3.53 | +$0.23 |
| Q1 2025 | -$3.16 | +$1.24 |
| Q4 2024 | -$2.90 | +$2.18 |
BCYC is still losing money, but far less than before: $2.03 per share over the past year, against $5.08 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BCYC on earnings quality, reporting a profit while its opponent remains loss making.
BCYC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $34.1M | +190% |
| Q2 2026 | $629K | -78% |
| Q1 2026 | $887K | -91% |
| Q4 2025 | $48M | +1193% |
| Q3 2025 | $11.7M | +338% |
| Q2 2025 | $2.9M | -69% |
| Q1 2025 | $10M | -49% |
| Q4 2024 | $3.7M | -30% |
BCYC's revenue is growing: $34M last quarter, up 190% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -40% | +519 points |
| Q2 2026 | -8674% | -5708 points |
| Q1 2026 | -7382% | -6679 points |
| Q4 2025 | -52% | +1773 points |
| Q3 2025 | -559% | +1827 points |
| Q2 2025 | -2966% | -2468 points |
| Q1 2025 | -704% | -541 points |
| Q4 2024 | -1825% | -807 points |
BCYC's operating margin was −40% last quarter, up 519 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BCYC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BCYC on profitability, with a higher operating margin.
BCYC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40.6M | +$31.2M |
| Q2 2026 | -$49.9M | +$23.4M |
| Q1 2026 | -$66.6M | +$20.3M |
| Q4 2025 | -$19.9M | -$10.2M |
| Q3 2025 | -$71.8M | -$31.6M |
| Q2 2025 | -$73.3M | -$28.2M |
| Q1 2025 | -$87M | -$16.1M |
| Q4 2024 | -$9.8M | +$37.6M |
BCYC has burned cash in almost every quarter: −$177M over the past year, against −$242M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BCYC on cash generation, producing positive trailing cash flow while its opponent burns cash.
BCYC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +175K shares |
| 1 year | +1% | +676K shares |
| 3 years | +77% | +30.4M shares |
| 5 years | +179% | +44.9M shares |
| Available history | +290% | +52.1M shares |
BCYC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BCYC Net Leverage
BCYC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BCYC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 20.6 | Neutral |
BCYC's weekly RSI is 39 (neutral) and its Stochastic is 21 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BCYC PE vs Healthcare Sector
BCYC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BCYC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.59 | 3.9% below |
| 20 week MA | $3.89 | 11% below |
| 50 week MA | $4.79 | 28% below |
| 100 week MA | $6.92 | 50% below |
| 200 week MA | $14.4 | 76% below |
BCYC is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BCYC on trend strength, trading above more of its moving averages.
BCYC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.07 | $19.9 | +119% |
| 2021 | $19.9 | $60.3 | +203% |
| 2022 | $60.3 | $30.0 | -50% |
| 2023 | $30.0 | $18.1 | -40% |
| 2024 | $18.1 | $14.6 | -20% |
| 2025 | $14.6 | $6.82 | -53% |
| 2026 YTD | $6.82 | $3.45 | -49% |
BCYC has finished four years in a row lower, and it's down 49% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BCYC on returns for 2026, with the stronger performance.